Equity Profile

DXCM

DexCom, Inc.

Health CareHealth Care Equipment$34.5B

Jul29Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

DexCom, Inc. is a healthcare company that specializes in continuous glucose monitoring systems for people with diabetes....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating income.

0.67

Revenue

Total revenue reflects the company's sales performance and growth potential, which is vital for assessing overall business health.

1.3B

Wall Street expectations, options signals, track record, and call prep available with Pro.

DXCM Q2-2026 Earnings Preview

Context

Company Snapshot

DexCom, Inc. is a healthcare company that specializes in continuous glucose monitoring systems for people with diabetes. As part of the health care equipment sector, DexCom plays a crucial role in improving diabetes management and patient outcomes through innovative technology.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+0.22%

Avg Stock Reaction

-0.38%

Last Quarter Recap

In Q1 2026, DexCom reported an EPS of $0.56, surpassing expectations by 19.66%. The stock reacted positively, gaining 3.46% the following day.

Management Promises & Guidance

Continued focus on expanding product offerings.
Commitment to improving customer support and engagement.
Plans to enhance manufacturing capabilities.

Expectations

Wall Street Expectations

Analysts expect DexCom to report solid earnings driven by strong demand for its glucose monitoring systems. The consensus EPS is set at $0.67, with revenue anticipated at $1.3 billion.

Bull Case

If DexCom beats expectations, it could signal strong market demand and effective cost management, potentially leading to a positive stock reaction.

Bear Case

Conversely, if the company misses estimates, it may raise concerns about market competition and product adoption, leading to a negative reaction.

Key Metrics to Watch

EPS

0.67

Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating income.

Revenue

1.3B

Total revenue reflects the company's sales performance and growth potential, which is vital for assessing overall business health.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will DexCom's EPS exceed the consensus estimate of $0.67?

A beat on EPS could indicate stronger profitability and operational efficiency, which would likely boost investor confidence.

What is the outlook for revenue growth given the consensus of $1.3 billion?

Revenue growth is critical for assessing the company's market position and ability to compete effectively in the healthcare sector.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the impact of new product launches on revenue growth this quarter, as historical trends show a stronger adoption rate than anticipated.

Supporting Evidence

Recent product enhancements have received positive feedback from customers, indicating potential for higher sales.

The options market suggests a significant move, indicating that investors are bracing for a surprise.

DexCom's previous earnings surprises have shown a trend of exceeding expectations, which may not be fully priced in.

Key Risk

If the new product sales significantly outperform expectations, it could lead to a substantial upward revision in revenue forecasts.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is pivotal as it will reflect the company's ability to sustain growth in a competitive environment.

Bull Confirmed If

An EPS of $0.70 or higher would confirm strong demand and operational efficiency.

Bear Confirmed If

An EPS below $0.62 would raise concerns about market competitiveness and product adoption.

Pre-Earnings Positioning

Options Market

Implied Move

±14.1%

Historical Avg

±2.1%

Pricing rich

The options market is pricing in a significant potential move, suggesting that investors expect volatility around the earnings report.

Options are pricing ±14.1% while DXCM has averaged ±2.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

46.5%

Calls (390K)P/C Ratio: 0.28Puts (105K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If DexCom beats expectations, history suggests a potential stock increase of around 1% on the next trading day, confirming strong demand.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further commentary from management.

Miss

Should DexCom miss estimates, history indicates a potential decline of about 0.65% on the next trading day, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on the performance of new product launches and their impact on sales.
2Any updates on customer engagement initiatives and support improvements.
3Management's outlook on competitive pressures in the glucose monitoring market.
4Insights into manufacturing capacity and supply chain efficiency.
5Comments on future growth strategies and market expansion plans.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

DYNBMO

Dyne Therapeutics, Inc.

PreviewView

Jul27

ARLPBMO

Company Snapshot

DexCom, Inc. is a healthcare company that specializes in continuous glucose monitoring systems for people with diabetes....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating income.

0.67

Revenue

Total revenue reflects the company's sales performance and growth potential, which is vital for assessing overall business health.

1.3B

Wall Street expectations, options signals, track record, and call prep available with Pro.

DXCM Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+0.22%

Avg Stock Reaction

-0.38%

Last Quarter Recap

In Q1 2026, DexCom reported an EPS of $0.56, surpassing expectations by 19.66%. The stock reacted positively, gaining 3.46% the following day.

Management Promises & Guidance

Continued focus on expanding product offerings.
Commitment to improving customer support and engagement.
Plans to enhance manufacturing capabilities.

Expectations

Wall Street Expectations

Analysts expect DexCom to report solid earnings driven by strong demand for its glucose monitoring systems. The consensus EPS is set at $0.67, with revenue anticipated at $1.3 billion.

Bull Case

If DexCom beats expectations, it could signal strong market demand and effective cost management, potentially leading to a positive stock reaction.

Bear Case

Conversely, if the company misses estimates, it may raise concerns about market competition and product adoption, leading to a negative reaction.

Key Metrics to Watch

EPS

0.67

Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating income.

Revenue

1.3B

Total revenue reflects the company's sales performance and growth potential, which is vital for assessing overall business health.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will DexCom's EPS exceed the consensus estimate of $0.67?

A beat on EPS could indicate stronger profitability and operational efficiency, which would likely boost investor confidence.

What is the outlook for revenue growth given the consensus of $1.3 billion?

Revenue growth is critical for assessing the company's market position and ability to compete effectively in the healthcare sector.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the impact of new product launches on revenue growth this quarter, as historical trends show a stronger adoption rate than anticipated.

Supporting Evidence

Recent product enhancements have received positive feedback from customers, indicating potential for higher sales.

The options market suggests a significant move, indicating that investors are bracing for a surprise.

DexCom's previous earnings surprises have shown a trend of exceeding expectations, which may not be fully priced in.

Key Risk

If the new product sales significantly outperform expectations, it could lead to a substantial upward revision in revenue forecasts.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is pivotal as it will reflect the company's ability to sustain growth in a competitive environment.

Bull Confirmed If

An EPS of $0.70 or higher would confirm strong demand and operational efficiency.

Bear Confirmed If

An EPS below $0.62 would raise concerns about market competitiveness and product adoption.

Pre-Earnings Positioning

Options Market

Implied Move

±14.1%

Historical Avg

±2.1%

Pricing rich

The options market is pricing in a significant potential move, suggesting that investors expect volatility around the earnings report.

Options are pricing ±14.1% while DXCM has averaged ±2.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

46.5%

Calls (390K)P/C Ratio: 0.28Puts (105K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If DexCom beats expectations, history suggests a potential stock increase of around 1% on the next trading day, confirming strong demand.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further commentary from management.

Miss

Should DexCom miss estimates, history indicates a potential decline of about 0.65% on the next trading day, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on the performance of new product launches and their impact on sales.
2Any updates on customer engagement initiatives and support improvements.
3Management's outlook on competitive pressures in the glucose monitoring market.
4Insights into manufacturing capacity and supply chain efficiency.
5Comments on future growth strategies and market expansion plans.